focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks lower as investors tread cautiously

Mon, 31st Mar 2014 16:58

- ECB under pressure to move on rates- Stocks erase gains but near three-week highs- Copper futures lower ahead of manufacturing PMIs- Small Russian troop pull backtechMARK 2,764.65 +0.09%FTSE 100 6,598.37 -0.26%FTSE 250 16,273.72 +0.57%UK stocks ended the day slightly lower as investors opted to bide their time ahead of Friday's US non-farm payrolls report and a barrage of data on the global manufacturing sector due out tomorrow.Worth noting, copper futures were changing hands at $303 per pound in early morning trading on COMEX, moving lower by approximately 0.51%. Acting as a backdrop, and linked to the above, a fair bit of market commentary could be seen referencing the risk of a steeper than expected slowdown in China's economy. Further weighing on sentiment was a weaker than expected reading on mortgage approvals for February. Data from the Bank of England revealed a decline to a monthly pace of 70,309, in comparison to the 76,753 seen in the month before and the 75,000 expected by the consensus. In parallel, European stocks were also getting weighed down by traders' cautiousness ahead of Thursday European Central Bank policy meeting. Reza Moghadam, Director of the IMF's European Department said today the central bank still has room to cut interest rates in face of the considerable downwards pressure on inflation.Figures released on Monday showed the annual rate of Eurozone consumer price inflation easing to a five-year low of 0.5% in March, down from 0.8% in February and below the 0.6% consensus forecast. The 'core' rate, which excludes volatile factors such as energy, food, alcohol and tobacco, fell to 0.8% from 1%, as expected.Ben May, European Economist at Capital Economics said that the slowdown in annual price rises was probably due to the timing of Easter, which fell in March last year. "But while we expect both headline and core inflation to pick up in April, underlying inflationary pressures will remain weak thanks to the large amount of spare economic capacity and the euro's strength," he said.May said it is "only a matter of time" before the European Central Bank (ECB) will decide that it needs to take "further policy action to prevent a worsening of the medium-term inflation outlook".Speaking in afternoon, Ukrainian Defence Ministry official Major-General Oleksandr Rozmaznin said the number of Russian troops deployed on the border with Ukraine is decreasing. He was unable to confirm numbers. "The number has definitely dropped and it (the situation) has calmed down. We won't rejoice and shout 'Hurray'. It doesn't matter how many of them there are, we just need to make sure our defences are strong," he said, according to Reuters.Babcock gains on nuclear contractEngineering group Babcock led gains after its joint venture, Cavendish Fluor Partnership, was selected as the preferred bidder for a UK government contract to manage the decommissioning of nuclear sites. According to the Nuclear Decommissioning Authority the 14-year contract is worth up to £7bn.Some miners also did well, including Anglo American and Rio Tinto, after Credit Suisse named them as its top picks in the metals and mining sector. Anglo was applauded for its restructuring potential, while the bank said that Rio's shareholder returns could be "larger and [...] sooner than any of its peer group".Analysts at Barclays raised their target price on ARM Holdings from 1125p to 1200p while reiterating their overweight recommendation.Insurance stocks such as Resolution and Aviva edged higher as share prices attempted to recover from the sell-off that ensued on Friday on the news of a regulatory investigation into the industry. The Financial Conduct Authority is set to outline its report today.Power systems giant Rolls-Royce gained after winning a $50m one-year contract to support the US Marines Corps fleet of KC-130J air-to-air refuelling tankers. GlaxoSmithKline declined after saying the third phase of its study of darpladib failed to meet its target for the prevention of stroke.Peel Hunt upgraded stock in African Barrick Gold to 'buy' from 'hold'.FTSE 100 - RisersBabcock International Group (BAB) 1,347.00p +4.26%Pearson (PSON) 1,063.00p +2.31%Mondi (MNDI) 1,049.00p +2.24%ARM Holdings (ARM) 998.00p +2.10%WPP (WPP) 1,237.00p +1.81%Rio Tinto (RIO) 3,337.50p +1.77%BAE Systems (BA.) 414.20p +1.67%Petrofac Ltd. (PFC) 1,438.00p +1.55%G4S (GFS) 241.50p +1.51%Aviva (AV.) 477.00p +1.45%FTSE 100 - FallersSSE (SSE) 1,469.00p -2.78%Shire Plc (SHP) 2,945.00p -2.52%St James's Place (STJ) 825.00p -2.25%Associated British Foods (ABF) 2,781.00p -1.73%GlaxoSmithKline (GSK) 1,591.50p -1.64%Sports Direct International (SPD) 852.00p -1.62%AstraZeneca (AZN) 3,876.50p -1.55%Tullow Oil (TLW) 748.50p -1.51%Next (NXT) 6,600.00p -1.49%Whitbread (WTB) 4,162.00p -1.44%FTSE 250 - RisersEvraz (EVR) 79.70p +10.62%African Barrick Gold (ABG) 263.50p +6.51%Xaar (XAR) 938.00p +5.99%CSR (CSR) 725.50p +4.54%Imagination Technologies Group (IMG) 203.20p +4.26%AL Noor Hospitals Group (ANH) 1,074.00p +3.67%Informa (INF) 528.50p +3.53%Alent (ALNT) 317.00p +3.49%Debenhams (DEB) 79.95p +3.09%Daejan Holdings (DJAN) 4,890.00p +3.06%FTSE 250 - FallersFisher (James) & Sons (FSJ) 1,463.00p -2.27%esure Group (ESUR) 279.70p -2.24%Entertainment One Limited (ETO) 330.00p -2.22%NMC Health (NMC) 504.50p -2.04%Howden Joinery Group (HWDN) 372.10p -1.85%Carphone Warehouse Group (CPW) 324.90p -1.84%Cairn Energy (CNE) 166.90p -1.71%EnQuest (ENQ) 124.00p -1.67%Direct Line Insurance Group (DLG) 237.50p -1.66%Soco International (SIA) 396.00p -1.49%AB
More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.